N/A
N=34
A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects
Erythema · Edema
Bottom Line
View on ClinicalTrials.gov: NCT02737592 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcome: Primary: Number of Subjects With Observed Local Erythema Based on 5 Point Scale — 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Trojan "Simply Pleasure" Personal Lubricant (Device)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Church & Dwight Company, Inc.
- Primary completion
- Apr 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With Observed Local Erythema Based on 5 Point Scale |
— | — |
| PRIMARY Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale |
— | — |
Summary
To evaluate the safety of a personal lubricant when used at least four times weekly for two weeks (including at least twice weekly during sexual intercourse for subjects with monogamous male partners), in a population consisting of healthy females.
Eligibility Criteria
Inclusion Criteria
- no participation in a similar study 2-weeks prior
- may be post-menopausal or have had a hysterectomy
- if sexually active, and of child bearing potential, subjects is using adequate non-barrier method of birth control
- free from any vaginal disorders
- sexually active and in a monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study or is not sexually active
- personal lubricant user and agrees to replace her usual personal lubricant with the investigational product
- can start regardless of where they are in their cycles
- agrees to use the provided investigational product at least four time weekly over the two week study period
- exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline exam
- willing to refrain from introducing any new vaginal products, or using vaginal medications or local contraceptives during study
- agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area
- willing to use a urine pregnancy test provided to them at baseline and on third visit
- standard medical history form on file
- signed informed consent
- completed HIPAA
- dependable and able to follow directions as outlined
- receives a score of 0 or 0.5 for erythema and edema; and 0 for sensorial irritation (burning, stinging, itching and dryness) during the first examination.
Exclusion Criteria
- pregnant, nursing or planning a pregnancy
- currently using or has used within two weeks prior to the study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories or antihistamines
- known allergies to vaginal or any cosmetic products
- reports history of recurrent bladder, vaginal infections or incontinence
- exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation
- uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception
- participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation
- receives a score higher than 0/5 for erythema, edema or >0 for burning, stinging, or itching, during first examination or shows any other sign of mucosal irregularities
Data sourced from ClinicalTrials.gov (NCT02737592). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.